Home       About       Policy Forums       Interest Groups       Annual Meeting       Awards       Journal       Membership


Ukraine 2021-23

Rabia Kahveci is Senior Technical Advisor for Pharmaceutical Policy and Governance in the SAFEMed project, in Kyiv Ukraine since October 2018. SAFEMed project is a USAID funded and MSH led project that supports Ukrainian government. SAFEMed applies health system strengthening best practices to create evidence-based interventions and strengthen Ukraine’s pharmaceutical system. Her area of responsibility is to support priority setting and HTA, including and beyond capacity building and HTA institutionalization in Ukraine. Ukraine sets an excellent example of a LMIC with a recent rapid HTA institutionalization along with the legislative introductions of mandatory HTA and development of MEA (Managed Entry Agreements).

Besides her full time work at SAFEMed, she has been an active member of the HTAi for many years and served in the Board of Directors as ex officio (2013-2014), Director (2014-2017) and re-elected Director (2017-2020). During these years she chaired Annual Meeting Committee; co- chaired International Scientific Program Committee of HTAi Annual Meeting in Rome (2017); acted as member of ISPC in over five annual meetings; contributed to strategic plan update and recently to Covid-19 response team; chaired Developing Countries Interest Group, and currently co-chairing Medical Devices Interest Group. She chaired the Organizing Committee of HTAi Regional Meeting hosted by Ukraine, in September 2020, which hosted over 150 colleagues from the region. She also chairs the Eurasian HTA Initiative that has members from 9 countries from Balkans and Central Asia. She actively joined ISPOR meetings and also participated in ISPOR Europe’s HTA Roundtable for four years. She acted as the President of the Turkish Evidence-Based Medicine Society for eight years.

Prior to her position with SAFEMed, she was the director of a hospital-based HTA center in Turkey (ANHTA) that covered HTA, innovation for medical devices, and real-world evidence. She was a professor of family medicine in the same hospital. She contributed to several national and international projects around HTA, including EUnetHTA and AdHopHTA. ANHTA showed an impact of 2.5 million euros savings in 3 years, and stood as an outstanding example for HB- HTA at the global level. She served as the national clinical quality coordinator of the Turkish Ministry of Health in 2017, where she coordinated all activities involving HTA, clinical guidelines and quality.

Prior to ANHTA, she served as a member of the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during the transition to universal health coverage and was a co-author of the reimbursement guidelines. She worked in the Turkish Medicines Agency on pricing and reimbursement of pharmaceuticals and led the HTA work of the Agency. She currently lives in Kyiv, Ukraine with her two children. An academic and medical doctor by background, with a degree in HTA, she authored over 150 peer-reviewed articles, 8 books and delivered over 300 presentations in international meetings on HTA.

HTAi is The ONLY Global Society Championing Equitable, Responsive, And Cutting-Edge Health Technology Assessment (HTA). As a community of multidisciplinary advisors, academics, scientists, professionals, public & private organizations, students, and citizen members.Everything we do is dedicated to better health for all people and the future of HTA worldwide.

Become A Member Today

    Copyright © 2021. All Rights Reserved.